Chargement en cours...
Profile of Trastuzumab Deruxtecan in the Management of Patients with HER2-Positive Unresectable or Metastatic Breast Cancer: An Evidence-Based Review
Trastuzumab deruxtecan is a novel antibody–drug conjugate for the treatment of advanced solid tumors, including breast cancer, which overexpress or have amplification of the human epidermal growth factor receptor 2 (HER2). The novel structure of this exciting new agent means that it can deliver a hi...
Enregistré dans:
| Publié dans: | Breast Cancer (Dove Med Press) |
|---|---|
| Auteurs principaux: | , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Dove
2021
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7920506/ https://ncbi.nlm.nih.gov/pubmed/33658846 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/BCTT.S245024 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|